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Background
Cerebral infarction is an ischemic stroke resulting from
a disturbance in the blood vessels supplying blood to
the brain, being the leading cause of physical and cogni-
tive disabilities in adults [1]. The currently approved
administration of thrombolytic agents is effective only
within about the first 3 hours poststroke [2]. Recent stu-
dies have demonstrated that administration of growth
factors can reduce stroke size or functional deficits [3].
Among the factors, the granulocyte colony-stimulating
factor (G-CSF) demonstrated ability to promote differ-
entiation of hematopoietic cells, as well as neurogenesis
and promoting formation of new synapses [4,5]. There-
fore, the aim of this study was to evaluate if the protec-
tive role of G-CSF in cerebral ischemia is associated
with the maintenance of muscle strength.
Methods
Swiss webster mice (Mus musculus) males (n = 16),
weighing approximately 30 g, underwent global cerebral
ischemia. Was occluded common carotid arteries for 80
minutes, and after this period the blood flow of the
common carotid artery was released, while the arterial
blood supply to the left remained interrupted. The
stroke animals received vehicle (5% glucose solution) or
were treated with G-CSF at a dose of 100 mg /kg /day,
administering it after 24 hours of treatment. All the
experimental procedures were performed in accordance
withNational Institutes of Health (NIH) guidelines, and
study protocols were previously approved by the Institu-
tional Animal Care and Use Committee (CEUA Protocol
# 011/2011). The measurement of the strength of the
mice was performed in the pre and post surgery through
software coupled to a force transducer. The
quantification of the area of cerebral infarction using
2,3,5-triphenil tetrazolium chloride was established by
morphometric analysis using Image J program (NIH).
The data are presented as means ± SEM. Statistical ana-
lysis was performed using Student’s t test for
comparison of groups using the software Prism® 5.0
(GraphPad, San Diego, CA, USA). p values < 0.05 were
considered to be statistically significant.
Results and conclusions
A significant increase in the number of circulating leuko-
cytes in the animals treated with G-CSF (= AVE + vehicle
2,550 ± 283/mm3 vs. G-CSF + AVE = 15,650 ± 1,294/
mm3, p < 0.01) was observed. The strength after surgery
was significantly higher (p <0.05), in the group treated
with G-CSF (88 ± 4 g; t value = 0.0473) when compared
with vehicle group (71 ± 5 g). The areal extent of cerebral
infarction was significantly lower (p < 0.05) in animals
treated with G-CSF (0.205 ± 0.03 cm2; Student t value =
0.0331) compared to the control group (0.401 ± 0.07 cm2).
Our results demonstrate the neuroprotective effect of
G-CSF in mice undergoing ischemic brain, thereby con-
tributing to the reduction of neurofunctional impair-
ment caused by stroke, as the maintenance of strength
in the treated group.
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